Contribution of JAK2 mutations to T cell lymphoblastic lymphoma development
The JAK STAT pathway has a substantial role in lymphoid precursor cell proliferation, survival and differentiation. Nonetheless, the contribution of JAK2 to T cell lymphoblastic lymphoma (T LBL) development remains poorly understood. We have identified one activating TEL JAK2 translocation and four missense mutations accumulated in 2 out of 16 T LBL samples. Two of them are novel JAK2 mutations and the other two are reported for the first time in T LBL. Notably, R683G and I682T might have arisen owing to RNA editing. Mutated samples showed different mutated transcripts suggesting sub clonal heterogeneity. Functional approaches revealed that two JAK2 mutations (H574R and R683G) constitutively activate JAK STAT signaling in g2A cells and can drive the proliferation of BaF3 EpoR cytokine dependent cell line. In addition, aberrant hypermethylation of SOCS3 might contribute to enhance the activation of JAK STAT signaling. Of utmost interest is that primary T LBL samples harboring JAK2 mutations exhibited increased expression of LMO2, suggesting a mechanistic link between JAK2 mutations and the expression of LMO2, which was confirmed for the four missense mutations in transfected g2A cells. We therefore propose that active JAK2 contribute to T LBL development by two different mechanisms, and that the use of pan JAK inhibitors in combination with epigenetic drugs should be considered in future treatments.
Leukemia